Aapti Khanna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aapti Khanna has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Abdelsimar Tan Omar
Division of Neurosurgery, Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, Canada
1 shared publication Alisha Anand
Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
1 shared publicationAnish Puri
Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
1 shared publicationBill Wang
Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
1 shared publication- Chirayu R. Chokshi
McMaster University 1 Department of Biochemistry and Biomedical Sciences Hamilton, Canada
1 shared publication Chitra Venugopal
Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
1 shared publication
Latest Publications
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eaea8381
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target
Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eaea8381
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target
Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.